Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07465276) titled 'Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC' on March 6.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Dana-Farber Cancer Institute
Condition:
Head and Neck Squamous Cell Carcinoma (HNSCC)
Squamous Cell Carcinoma of the Head and Neck
Intervention:
Drug: Ficerafusp alfa
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: April 1, 2026
Target Sample Size: 32
Countries of Recruitment:
United States
To know more, visit https://clini...